M
Michael D. Radmacher
Researcher at Ohio State University
Publications - 77
Citations - 13454
Michael D. Radmacher is an academic researcher from Ohio State University. The author has contributed to research in topics: Leukemia & BAALC. The author has an hindex of 40, co-authored 77 publications receiving 12921 citations. Previous affiliations of Michael D. Radmacher include Duke University & Kenyon College.
Papers
More filters
Journal ArticleDOI
MicroRNA (miR) expression signatures in molecular subsets of cytogenetically normal (CN) acute myeloid leukemia (AML): A Cancer and Leukemia Group B (CALGB) study
Michael D. Radmacher,G. Marcucci,Peter Paschka,Tamara Vukosavljevic,Susan P. Whitman,Amy S. Ruppert,K. Mrózek,Jonathan E. Kolitz,Richard A. Larson,Clara D. Bloomfield +9 more
TL;DR: Aerrantly expressed miRs contribute to malignant transformation by hybridizing to specific mRNA targets and suppressing their translation into proteins and in CN AML, the largest cytotoxic cells have been identified.
Journal ArticleDOI
Aberrant Gene Expression of BAALC and ERG in Older [≥60 Years (y)] De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): A Cancer and Leukemia Group B (CALGB) Study.
Sebastian Schwind,Guido Marcucci,Kati Maharry,Krzysztof Mrózek,Michael D. Radmacher,Kelsi B. Holland,Heiko Becker,Susan P. Whitman,Yue-Zhong Wu,Maria R. Baer,Bayard L. Powell,Andrew J. Carroll,Michael A. Caligiuri,Richard A. Larson,Clara D. Bloomfield +14 more
TL;DR: Lower expression of both BAALC & ERG associated with better outcome in older CN-AML pts even in the context of other established prognostic molecular markers, but have different impact on age-groups.
Journal ArticleDOI
MiR-3151, a Novel MicroRNA Embedded in BAALC, Is Only Weakly Co-Expressed with Its Host Gene and Independently Impacts on the Clinical Outcome of Older Patients (Pts) with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)
Ann-Kathrin Eisfeld,Guido Marcucci,Kati Maharry,Sebastian Schwind,Michael D. Radmacher,Deedra Nicolet,Heiko Becker,Susan P. Whitman,Klaus H. Metzeler,Krzysztof Mrózek,Yue-Zhong Wu,Maria R. Baer,Bayard L. Powell,Thomas H. Carter,Joseph O. Moore,Jonathan E. Kolitz,Meir Wetzler,Michael A. Caligiuri,Richard A. Larson,Stephan M. Tanner,Albert de la Chapelle,Clara D. Bloomfield +21 more
TL;DR: It is hypothesized that miR-3151 might be co-expressed with BAALC and contributes alone or in concert with its host to poor prognostic impact in older CN-AML.
Journal ArticleDOI
Poor Outcome of RUNX1-Mutated (RUNX1-mut) Patients (Pts) with Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) and Associated Gene- and MicroRNA (miR) Expression Signatures,
Jason H. Mendler,Kati Maharry,Michael D. Radmacher,Krzysztof Mrózek,Jessica Kohlschmidt,Deedra Nicolet,Heiko Becker,Klaus H. Metzeler,Sebastian Schwind,Susan P. Whitman,William Blum,Bayard L. Powell,Jonathan E. Kolitz,Thomas H. Carter,Meir Wetzler,Joseph O. Moore,Andrew J. Carroll,Maria R. Baer,Richard A. Larson,Michael A. Caligiuri,Guido Marcucci,Clara D. Bloomfield +21 more
TL;DR: A relatively large study testing the prognostic impact of RUNX1 muts in primary CN-AML pts treated similarly with intensive cytarabine/anthracycline-based 1 st -line therapy and without alloSCT in CR1 found that RUNX 1 muts remained associated with lower CR rate in multivariable models.
Journal ArticleDOI
miR-3151 Interplays With its Host Gene BAALC and Independently Impacts on Outcome of Older Patients With Cytogenetically Normal Acute Myeloid Leukemia by Direct Deregulation of TP53
Ann-Kathrin Eisfeld,Guido Marcucci,Kati Maharry,Kati Maharry,Sebastian Schwind,Michael D. Radmacher,Michael D. Radmacher,Deedra Nicolet,Deedra Nicolet,Heiko Becker,Krzysztof Mrózek,Susan P. Whitman,Klaus H. Metzeler,Jason H. Mendler,Yue-Zhong Wu,Sandya Liyanarachchi,Ravi Patel,Maria R. Baer,Bayard L. Powell,Thomas H. Carter,Joseph O. Moore,Jonathan E. Kolitz,Meir Wetzler,Michael A. Caligiuri,Richard A. Larson,Stephan M. Tanner,Albert de la Chapelle,Clara D. Bloomfield +27 more
TL;DR: 903 miR-3151 Interplays With its Host Gene BAALC and Independently Impacts on Outcome of Older Patients With Cytogenetically Normal Acute Myeloid Leukemia by Direct Deregulation of TP53